570 related articles for article (PubMed ID: 33609539)
1. A double edged-sword - The Complement System during SARS-CoV-2 infection.
Santiesteban-Lores LE; Amamura TA; da Silva TF; Midon LM; Carneiro MC; Isaac L; Bavia L
Life Sci; 2021 May; 272():119245. PubMed ID: 33609539
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 Causes a Different Cytokine Response Compared to Other Cytokine Storm-Causing Respiratory Viruses in Severely Ill Patients.
Olbei M; Hautefort I; Modos D; Treveil A; Poletti M; Gul L; Shannon-Lowe CD; Korcsmaros T
Front Immunol; 2021; 12():629193. PubMed ID: 33732251
[TBL] [Abstract][Full Text] [Related]
3. Rationale for targeting complement in COVID-19.
Polycarpou A; Howard M; Farrar CA; Greenlaw R; Fanelli G; Wallis R; Klavinskis LS; Sacks S
EMBO Mol Med; 2020 Aug; 12(8):e12642. PubMed ID: 32559343
[TBL] [Abstract][Full Text] [Related]
4. Surviving the Rookie Virus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2): The Immunopathology of a SARS-CoV2 Infection.
Tsai SF; Lu KY; Chuang HM; Liu CA
Cell Transplant; 2021; 30():963689721993769. PubMed ID: 33840257
[TBL] [Abstract][Full Text] [Related]
5. The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections.
Zhang YY; Li BR; Ning BT
Front Immunol; 2020; 11():2033. PubMed ID: 32922406
[TBL] [Abstract][Full Text] [Related]
6. Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19.
Laurence J; Mulvey JJ; Seshadri M; Racanelli A; Harp J; Schenck EJ; Zappetti D; Horn EM; Magro CM
Clin Immunol; 2020 Oct; 219():108555. PubMed ID: 32771488
[TBL] [Abstract][Full Text] [Related]
7. A plea for the pathogenic role of immune complexes in severe Covid-19.
Vuitton DA; Vuitton L; Seillès E; Galanaud P
Clin Immunol; 2020 Aug; 217():108493. PubMed ID: 32526273
[No Abstract] [Full Text] [Related]
8. A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2.
Atzrodt CL; Maknojia I; McCarthy RDP; Oldfield TM; Po J; Ta KTL; Stepp HE; Clements TP
FEBS J; 2020 Sep; 287(17):3633-3650. PubMed ID: 32446285
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Immune Response between SARS, MERS, and COVID-19 Infection, Perspective on Vaccine Design and Development.
Ansariniya H; Seifati SM; Zaker E; Zare F
Biomed Res Int; 2021; 2021():8870425. PubMed ID: 33564683
[TBL] [Abstract][Full Text] [Related]
10. Complement cascade in severe forms of COVID-19: Recent advances in therapy.
Chouaki Benmansour N; Carvelli J; Vivier E
Eur J Immunol; 2021 Jul; 51(7):1652-1659. PubMed ID: 33738806
[TBL] [Abstract][Full Text] [Related]
11. Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis.
Gralinski LE; Sheahan TP; Morrison TE; Menachery VD; Jensen K; Leist SR; Whitmore A; Heise MT; Baric RS
mBio; 2018 Oct; 9(5):. PubMed ID: 30301856
[TBL] [Abstract][Full Text] [Related]
12. The potential association between PARP14 and SARS-CoV-2 infection (COVID-19).
Tauber AL; Schweiker SS; Levonis SM
Future Med Chem; 2021 Mar; 13(6):587-592. PubMed ID: 33467912
[TBL] [Abstract][Full Text] [Related]
13. Innate Immune Responses to Highly Pathogenic Coronaviruses and Other Significant Respiratory Viral Infections.
Ahmed-Hassan H; Sisson B; Shukla RK; Wijewantha Y; Funderburg NT; Li Z; Hayes D; Demberg T; Liyanage NPM
Front Immunol; 2020; 11():1979. PubMed ID: 32973803
[TBL] [Abstract][Full Text] [Related]
14. MERS-CoV infection causes brain damage in human DPP4-transgenic mice through complement-mediated inflammation.
Jiang Y; Chen Y; Sun H; Zhang X; He L; Li J; Zhao G; Sun S
J Gen Virol; 2021 Oct; 102(10):. PubMed ID: 34704923
[TBL] [Abstract][Full Text] [Related]
15. Immunological map in COVID-19.
Li CH; Chiou HC; Lin MH; Kuo CH; Lin YC; Lin YC; Hung CH; Kuo CH
J Microbiol Immunol Infect; 2021 Aug; 54(4):547-556. PubMed ID: 34023234
[TBL] [Abstract][Full Text] [Related]
16. Complement as a target in COVID-19?
Risitano AM; Mastellos DC; Huber-Lang M; Yancopoulou D; Garlanda C; Ciceri F; Lambris JD
Nat Rev Immunol; 2020 Jun; 20(6):343-344. PubMed ID: 32327719
[TBL] [Abstract][Full Text] [Related]
17. Emerging Human Coronavirus Infections (SARS, MERS, and COVID-19): Where They Are Leading Us.
Kumar V
Int Rev Immunol; 2021; 40(1-2):5-53. PubMed ID: 32744465
[TBL] [Abstract][Full Text] [Related]
18. Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.
Mastellos DC; Pires da Silva BGP; Fonseca BAL; Fonseca NP; Auxiliadora-Martins M; Mastaglio S; Ruggeri A; Sironi M; Radermacher P; Chrysanthopoulou A; Skendros P; Ritis K; Manfra I; Iacobelli S; Huber-Lang M; Nilsson B; Yancopoulou D; Connolly ES; Garlanda C; Ciceri F; Risitano AM; Calado RT; Lambris JD
Clin Immunol; 2020 Nov; 220():108598. PubMed ID: 32961333
[TBL] [Abstract][Full Text] [Related]
19. [Involvement of the complement cascade in severe forms of COVID-19].
Chouaki Benmansour N; Carvelli J; Vivier É
Med Sci (Paris); 2021 Apr; 37(4):333-341. PubMed ID: 33835019
[TBL] [Abstract][Full Text] [Related]
20. Neurological Damage by Coronaviruses: A Catastrophe in the Queue!
Mishra R; Banerjea AC
Front Immunol; 2020; 11():565521. PubMed ID: 33013930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
